Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
155,7 INR | +0,81% |
|
-3,14% | +12,18% |
14/05 | PIRAMAL PHARMA LIMITED : giudizio positivo da Jefferies & Co. | ZM |
13/05 | Transcript : Piramal Pharma Limited, Q4 2024 Earnings Call, May 13, 2024 |
Attività
Numero di dipendenti: 6 719
Vendite per attività
INR in Milioni | 2023 | Peso | 2024 | Peso | Delta |
---|---|---|---|---|---|
Contract Development and Manufacturing Organisation
58,0
%
| - | - | 47 393 | 58,0 % | - |
Inhalation Anesthesia
20,1
%
| 14 503 | 20,5 % | 16 424 | 20,1 % | +13,25% |
Intrathecal Therapy
4,5
%
| 3 399 | 4,8 % | 3 677 | 4,5 % | +8,17% |
Injectable Anesthesia and Pain Management
3,0
%
| 2 493 | 3,5 % | 2 451 | 3,0 % | -1,66% |
Kids Wellness
2,8
%
| 1 870 | 2,6 % | 2 255 | 2,8 % | +20,63% |
Other Generic and Specialty Products
2,4
%
| 2 266 | 3,2 % | 1 961 | 2,4 % | -13,46% |
Skin Care
2,3
%
| 1 785 | 2,5 % | 1 863 | 2,3 % | +4,40% |
Analgesic
2,3
%
| 1 700 | 2,4 % | 1 863 | 2,3 % | +9,62% |
Multivitamin
1,8
%
| 1 275 | 1,8 % | 1 471 | 1,8 % | +15,39% |
Other India Consumer Healthcare
1,2
%
| 425 | 0,6 % | 981 | 1,2 % | +130,77% |
Gastro Intestinal
0,8
%
| 595 | 0,8 % | 686 | 0,8 % | +15,39% |
Women's Health
0,8
%
| 680 | 1,0 % | 686 | 0,8 % | +0,96% |
Vendite per regione
INR in Milioni | 2023 | Peso | 2024 | Peso | Delta |
---|---|---|---|---|---|
North America
41,0
%
| 31 867 | 45,0 % | 33 502 | 41,0 % | +5,13% |
Europe
25,0
%
| 14 163 | 20,0 % | 20 428 | 25,0 % | +44,23% |
India
20,0
%
| 14 163 | 20,0 % | 16 342 | 20,0 % | +15,39% |
Others
10,0
%
| 7 790 | 11,0 % | 8 171 | 10,0 % | +4,90% |
Japan
4,0
%
| 2 833 | 4,0 % | 3 268 | 4,0 % | +15,39% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Peter DeYoung
CEO | Chief Executive Officer | 46 | 04/03/20 |
Vivek Valsaraj
PSD | President | 51 | 10/06/20 |
Vinay Agrawal
COO | Chief Operating Officer | 60 | 05/04/20 |
Gagan Borana
IRC | Investor Relations Contact | - | - |
Prasanth M. S.
SAM | Sales & Marketing | 51 | 10/06/20 |
Vikram Duggal
HRO | Human Resources Officer | 50 | 08/01/20 |
Sameer Penkar
SAM | Sales & Marketing | - | 10/06/20 |
Corporate Secretary | - | 04/03/20 | |
Rashida Najmi
PRN | Corporate Officer/Principal | 58 | - |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Chairman | 43 | 04/01/21 | |
Neeraj Bharadwaj
BRD | Director/Board Member | 55 | - |
Director/Board Member | 76 | 09/02/21 | |
Director/Board Member | 52 | 30/03/22 | |
Vibha Paul Rishi
BRD | Director/Board Member | 64 | 29/09/22 |
Director/Board Member | 65 | 09/02/21 | |
Peter DeYoung
CEO | Chief Executive Officer | 46 | 04/03/20 |
Vivek Valsaraj
PSD | President | 51 | 10/06/20 |
Peter Stevenson
BRD | Director/Board Member | - | 30/03/22 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 1 320 816 324 | 354 235 407 ( 26,82 %) | 0 | 26,82 % |
Coordinate società
Piramal Pharma Ltd.
507, Skyline Wealth Space, 5th Floor C2 Wing, Skyline Oasis Complex
400086, Mumbai
+91 22 3802 3000
http://www.piramal.com/businesses/piramal-pharma/![Indirizzo Piramal Pharma Limited(543635)](https://cdn.zonebourse.com/static/address/145450989.png)
Settore
Vendite per attività
Vendite per regione
![Consenso](/images/consensus_flch.gif)
Revisioni EPS
Fatturato trimestrale - Indice di sorpresa
Variaz. 1 gen. | Capi. | |
---|---|---|
+59,97% | 827 Mrd | |
+38,38% | 634 Mrd | |
-6,18% | 350 Mrd | |
+15,61% | 319 Mrd | |
+8,44% | 294 Mrd | |
+12,68% | 240 Mrd | |
+14,40% | 221 Mrd | |
+0,04% | 219 Mrd | |
+9,68% | 167 Mrd |
- Borsa valori
- Azioni
- Azione PPLPHARMA
- Azione 543635
- Società Piramal Pharma Limited